Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Paris  >  Sanofi    SAN   FR0000120578

SANOFI

(SAN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

SANOFI : Buy rating from JP Morgan

04/08/2021 | 01:40am EDT

JP Morgan analyst Richard Vosser maintains his Buy rating on the stock. The target price remains unchanged at EUR 93.


© MarketScreener with dpa-AFX Analyser 2021
All news about SANOFI
03:41aMUCINOUS CYSTIC NEOPLASM PIPELINE : Emerging Therapies and Key pharma players in..
AQ
12:42aMARKET CHATTER : Sanofi Launches Its First China Research Institute
MT
04/15Activist investor Elliott takes multibillion pound stake in GSK, FT says
RE
04/15SANOFI  : Gets a Buy rating from UBS
MD
04/14SANOFI  : After Setbacks, Rollout of New TB Prevention Pills to Start in Six Dis..
AQ
04/14SANOFI  : JP Morgan reiterates its Buy rating
MD
04/13C4X DISCOVERY  : Up to EUR414 million Exclusive Worldwide Licensing Agreement wi..
AQ
04/13SWEDISH ORPHAN BIOVITRUM  : Sobi Doses First Patient In Phase 3 Trial Of Pediatr..
MT
04/13SWEDISH ORPHAN BIOVITRUM  : First patient dosed in phase 3 XTEND-Kids study with..
AQ
04/13SANOFI  : Declares Kiadis Offer Unconditional, All Offer Conditions Now Satisfie..
MT
More news
Financials
Sales 2021 36 894 M 44 179 M 44 179 M
Net income 2021 5 909 M 7 076 M 7 076 M
Net Debt 2021 7 285 M 8 723 M 8 723 M
P/E ratio 2021 17,8x
Yield 2021 3,88%
Capitalization 106 B 126 B 127 B
EV / Sales 2021 3,06x
EV / Sales 2022 2,80x
Nbr of Employees 99 412
Free-Float 88,7%
Chart SANOFI
Duration : Period :
Sanofi Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SANOFI
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Average target price 100,65 €
Last Close Price 84,61 €
Spread / Highest target 38,3%
Spread / Average Target 19,0%
Spread / Lowest Target -17,3%
EPS Revisions
Managers and Directors
NameTitle
Paul Hudson Chief Executive Officer & Director
Jean-Baptiste Chasseloup de Chatillon Chief Financial Officer & Executive Vice President
Serge Weinberg Chairman
John C. Reed EVP & Global Head-Research & Development
Nestle Frank Global Head-Immunology Therapeutic Research Area
Sector and Competitors
1st jan.Capitalization (M$)
SANOFI7.51%126 435
JOHNSON & JOHNSON1.91%422 260
ROCHE HOLDING AG-0.02%289 178
PFIZER INC.2.15%209 739
NOVARTIS AG-4.51%197 072
MERCK & CO., INC.-6.28%194 049